摘要
目的探讨伊立替康联合奈达铂治疗复发性小细胞肺癌的疗效和毒副反应。方法 31例复发性小细胞肺癌患者均接受伊立替康联合奈达铂治疗,并观察临床治疗效果和毒副反应。结果全组31例中,CR 5例,PR 18例,SD 4例,PD 4例,有效率为74.2%(23/31),疾病控制率为87.1%(27/31),中位生存期为13.2个月,1 a生存率为64.5%。毒副反应主要为轻度骨髓抑制、消化道反应。结论伊立替康联合奈达铂治疗复发性小细胞肺癌具有一定的有效性和安全性,值得进一步临床研究。
Objective To investigate the efficacy and toxicities of irinotecan plus nedaplatin in the treatment of recurrent small cell lung cancer. Methods Thirty-one patients with recurrent small cell lung cancer received the irinotecan plus nedaplatin chemotherapy,and the efficacy and toxicities were evaluated. Results Of the 31 cases, CR was observed in the 5 cases,PR in the 18 cases,SD in the 4 cases,PD in the 4 cases,the effective rate was 74. 2%（23 / 31）,the disease control rate was 87. 1%（27 / 31）,the median survival time was 13. 2 months,1-year survival rate was 64. 5% . The main toxicities were marrow suppression and gastrointestinal reaction. Conclusion Irinotecan plus nedaplatin is effective and safe in the treatment of recurrent small cell lung cancer.
出处
《肿瘤基础与临床》
2014年第2期122-123,共2页
journal of basic and clinical oncology
关键词
伊立替康
奈达铂
复发性小细胞肺癌
irinotecan
nedaplatin
recurrent small cell lung cancer
